BioLineRx Ltd. (BLRX) Form 6-K — Nov 18, 2026
BioLineRx entered a Purchase and Sale Agreement on November 17, 2026 to sell 80% of its future royalty rights on APHEXDA (motixafortide) net sales to SCOF Motixafortide Holdings, an affiliate of Soleus Capital Management, for a one-time payment of $5.6 million, with closing expected on or about November 30, 2026. The sold interest corresponds to a 14.4% effective royalty on APHEXDA net sales (out of an 18% royalty rate under the Ayrmid license); BioLineRx retains a 3.6% royalty, all milestone payments, and rights under its Asia partnership with Gloria Biosciences.
Key figures
- Purchase Price
- 5600000
- Ayrmid royalty rate
- 18%
- Royalty percent sold
- 80%
- Purchaser expense cap
- 100000
- Kreos partial prepayment
- 3000000
- Royalty percent retained
- 20%
- Effective royalty rate sold
- 14.4%
- Kreos remaining outstanding
- 2000000
- Effective royalty rate retained
- 3.6%
- Kreos minimum cash covenant eliminated
- 4000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.